Jordana E. Hoppe

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 116 citations · Full text

Medicine, Hypertonic Saline, Dornase Alfa +1

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 113 citations · Full text

Sputum induction improves detection of pathogens in children with cystic fibrosis

Jordana E. Hoppe, E. Towler, Brandie D. Wagner et al. · Pediatric Pulmonology · 2015 · 40 citations · Full text

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman et al. · The Lancet Respiratory Medicine · 2025 · 39 citations · Full text

Evaluation of surrogate measures of pulmonary function derived from electrical impedance tomography data in children with cystic fibrosis

Peter A. Muller, Jennifer L. Mueller, Michelle M. Mellenthin et al. · Physiological Measurement · 2018 · 36 citations